Homepage Top Section2

Upadacitinib (RINVOQ, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) is intended for those patients who have not shown adequate response, lost response or were intolerant to

In September last year, Stimufend received approval from the US Food and Drug Administration (FDA) to be used in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs that

TAKHZYRO is a completely human monoclonal antibody that particularly binds and reduces plasma kallikrein activity.   Before this approval, the only approved routine prophylaxis treatment options for children

The European Commission (EC) will now review the recommendation. On receiving approval, this would represent the third authorised indication for the therapy in the EU. Approved in the

Serving as the primary IND for TScan’s solid tumour programme, T-Plex will enable customised combinations of T cell receptor (TCR)-engineered T cell therapies (TCR-T) to be given to

The adeno-associated viral serotype rh10 (AAVrh10) gene therapy FBX-101 is delivered intravenously after hematopoetic stem cell transplant (HSCT) infusion. The designation for this lead adeno-associated virus (AAV) drug

The FDA is expected to complete the NDA review in October this year and stated that it currently has no plans to hold an advisory committee meeting to

Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) following two or more lines of

BTD for IBI351 (GFH925) has been granted to treat advanced non-small cell lung cancer (NSCLC) patients with KRASG12C mutation who have undergone at least one prior line of